e-Business in pharmaceutical industry

Revolution in biogenetics

The tensions between the rising costs of healthcare 

  (availability of new treatments & increasing demand) and 

  the ability & willingness of the society to cover these costs.

Competitive Pressure   

	Merger & acquisition
	Globalization
	Shorter patent exclusivity
	e-Technology
	Genomics
	Cost explosion
	Shareholder value
	Changing regulatory & political environment

Pharma Healthcare

	Scientific & technical breakthrough
	Pharmacogenomics
	Internet
	Partnering

       Opportunities

	Integrated disease management
	Faster & more precise therapies
	Better informed patients
	Increased cost efficiency
	Expanded business options
	New quality in communication

Accelerated pace of discovery

Shorter product life cycle

Complications / changes in patent law

Creation of near perfect information market and effect on relative roles of 

patients, doctors, payer, opinion leaders , etc.

Control of information flow and content by government

Dramatic changes in physical distribution

Increased importance of effect of pharmaceuticals on total healthcare costs

Multiplication of industry alliance

Accelerated industry consolidation

Exceed industry growth rate

Match industry gross margin

Operating expense growth slower than sales growth

Operating ratio at least at industry average 

Seamless communication along product supply chain

e-Purchasing

Collection, processing, and dissemination of information

e-Based human resources management system

Internal & external partnering & alliance

Knowledge management 

Gene Therapy : Transfer of selected genes into a host with the hope  of ameliorating or curing the disease state

Cell Therapy (Genome Therapy) : Transfer of entire cell, that have not been genetically modified, into a host with the hope that the transferred cells will engraft into and improve host functions

Strategic elements

• Integrating informatics

• Partnering

• Knowledge management

• Human genome data

Challenges / Bottlenecks

• Drugable targets

• Drug-like compounds

• Relevant patient population

      Disciplines

• Functional genomic

• Chemistry & biological profiles

• Pharmacogenomics

External collaboration & network  Oncology, Metabolism, Cardiovascular, Anti-invectives, RA/OA, Immunology , etc. Disease biology platforms

External collaboration & network Internal Genomic control disease groups Genomics technology platforms

Target

identification

Lead

identification

Candidate

identification

Pre-

Clinical

Clinical

Approval

10-

15

Years

Partnering              

Genomics

Informatics

Knowledge 

management

Lead identification

Candidate identification

Pre-clinical

Clinical

Approval

Years

Agricultural economy : 1850 - 1900

Industrial economy :  1900 - 2005

Information economy :1975 onward